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Oncology, Johns Hopkins University, Baltimore, MarylandABSTRACT The structure of a T cell receptor (TCR) and its affinity for cognate antigen are fixed, but T cells regulate binding
sensitivity through changes in lateral membrane organization. TCR microclusters formed upon antigen engagement participate
in downstream signaling. Microclusters are also found 3–4 days after activation, leading to enhanced antigen binding upon
rechallenge. However, others have found an almost complete loss of antigen binding four days after T cell activation, when
TCR clusters are present. To resolve these contradictory results, we compared binding of soluble MHC-Ig dimers by transgenic
T cells stimulated with a high (100 mM) or low (100 fM) dose of cognate antigen. Cells activated by a high dose of peptide bound
sixfold lower amounts of CD8-dependent ligand Kb-SIY than cells activated by a low dose of MHC/peptide. In contrast, both cell
populations bound a CD8-independent ligand Ld-QL9 equally well. Consistent with the differences between binding of CD8-
dependent and CD8-independent peptide/MHC, Fo¨rster resonance energy transfer (FRET) measurements of molecular prox-
imity reported little nanoscale association of TCR with CD8 (16 FRET units) compared to their association on cells stimulated by
low antigen dose (62 FRET units). Loss of binding induced by changes in lateral organization of TCR and CD8 may serve as
a regulatory mechanism to avoid excessive inflammation and immunopathology in response to aggressive infection.INTRODUCTIONT cells face the extraordinary challenge of finding as few as
1–10 cognate peptides presented in the context of major
histocompatibility complex (MHC) (1,2), masked by thou-
sands of irrelevant but structurally similar peptide/MHCs
on the opposing membrane. In addition, they must respond
to complex environmental stimuli which heighten or
dampen the response. As a result, T cells regulate the lateral
organization of surface receptors to achieve optimal ligand
recognition and activate downstream signaling cascades
after binding (3,4).
Antigen recognition by naı¨ve T cells induces lateral reor-
ganization of membrane proteins on several length scales
(5). The coreceptor CD8, which binds an invariant region
of the polymorphic MHC (6,7), mediates the association
of T cell receptor (TCR) with Src-family tyrosine kinases
to initiate downstream signaling (8). Robust activation
subsequently induces the formation of TCR and adhesion
structures, including bulls-eye-shaped immune synapses
(5,9) and TCR microclusters hundreds of nanometers in
diameter (10), which function to generate, sustain, and
terminate TCR signals (11,12).
TCR clusters can also be observed days after the initial
antigen recognition event, long after the antigen has been
cleared (13,14). In activated T cells, TCR clustering has
been reported to lead to enhanced binding of soluble
peptide-MHC (15). These studies stand in contrast with
observations that activated T cells may also lose the ability
to bind cognate soluble MHC (16–20). Changes in the CD8
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0006-3495/12/11/1890/9 $2.00the precise signals regulating binding behavior are poorly
understood. Furthermore, the contradiction between obser-
vations of enhanced binding and complete loss of binding
after activation has not been explained.
Here, we resolve this contradiction and show that changes
in nanoscale colocalization of TCR and CD8 determine
changes in binding after antigen stimulation. Primary stim-
ulation with a high dose but not low dose of antigen leads
to a transient spatial segregation of TCR and CD8. This
spatial segregation can impair CD8-dependent MHC bind-
ing antigen depending on antigen dose during primary stim-
ulation. Thus, despite having identical TCR, activated
T cells can have different MHC binding properties due to
changes in membrane organization of TCR and CD8.MATERIALS AND METHODS
Mice and reagents
2C TCR Rag/ transgenic mice were maintained as heterozygotes by
breeding on a C57/BL6 background. PME TCR/Thy1a Rag/ transgenic
mice were a gift from Nicholas Restive (National Institutes of Health
(NIH), Bethesda, MD) and maintained as homozygotes. Balb/C mice
were purchased from Jackson Laboratories (Bar Harbor, ME). All mice
were maintained according to Johns Hopkins University’s Institutional
Review Board. Peptides SIY (SIYRYYGL), SIIN (SIINFEKL), QL9
(QLSPFPFDL), mCMV (YPHFMPTNL), GP100 (KVPRNQDWL), and
ASN (ASNENMETH) were purchased from Genscript (Piscataway, NJ).
Fluorescently labeled monoclonal antibodies were purchased from
BioLegend (San Diego, CA). MHC monomers were obtained from the
NIH Tetramer Facility (Bethesda, MD).Cells
Cells used were obtained from homogenized mouse spleens after depletion
of red blood cells by hypotonic lysis. For mixed lymphocyte reaction,http://dx.doi.org/10.1016/j.bpj.2012.09.011
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irradiated Balb/C splenocytes as allogeneic stimulator cells for 4–7 days in
complete RPMI media supplemented with T cell factor, a cytokine cocktail
harvested from human plasma (21). For peptide activation, 10 106/mL 2C
splenocytes were activated by incubation with cognate peptide at the indi-
cated concentration in complete RPMI plus T cell factor.Preparation of MHC-Ig dimers
Soluble MHC-Ig dimers, Kb-Ig and Ld-Ig, were labeled fluorescently and
loaded with peptide as described previously (22). Unless otherwise indi-
cated, Kb-SIY and Ld-QL9 refer to soluble MHC-Ig dimer reagent of the
corresponding allele loaded with the indicated peptide. Labeling with
Alexa-488 or Alexa-657 succimidyl ester (Molecular Probes, Eugene,
OR) was performed at pH 7.4 and labeled protein was purified by dialysis
with a 50-kDa filter. Protein concentration was determined after labeling by
size-exclusion high-performance liquid chromatography. The efficiency of
fluorophore labeling was calculated by measuring absorbance at 280 nm
and fluorophore emission wavelength for the labeled proteins. Typically,
approximately one dye molecule was attached per MHC-Ig molecule.
Alexa Kb-Ig molecules were loaded with peptide by stripping at alkaline
condition (pH 11.5), and then refolded in the presence of 40-fold excess
peptide. Ld-Ig molecules were stripped under mildly acidic conditions
(pH 6.5) and refolded in the presence of 40-fold molar excess peptide
and twofold molar excess of human b2-microglobulin (23).MHC-Ig dimer binding assay
MHC-Ig dimer binding assays were performed as previously described in
Fahmy et al. (24). Briefly, CD8þ T cells were incubated at 4C at a concen-
tration of 107cells/mL in FACS wash buffer (phosphate-buffered saline
(PBS) þ 2% fetal calf serum (FCS) þ 0.05% sodium azide). A quantity
of 15-mL aliquots of cells was mixed with varying concentrations of
peptide-loaded, fluorescently labeled MHC-Ig dimers for 60–90 min.
Without any washing, cells were analyzed by flow cytometry on a
FACSCalibur flow cytometer (BD Biosciences, Mountain View, CA) and
analyzed using FlowJo software (Treestar, Ashland, OR). The mean
channel fluorescence was a measure of the amount of MHC-Ig dimer bound
on cells. A noncognate dimer (Kb-SIIN or Ld-MCMV) was used to account
for nonspecific binding which was subtracted from the total binding to yield
specific MHC-Ig binding. The specific binding was normalized to the
plateau of the binding isotherm and plotted against the peptide MHC-Ig
dimer concentration.Confocal microscopy
For confocal microscopy, T cells were stained with Alexa Fluor 488-labeled
H57 anti-mouse TCR antibody and Alex Fluor 647-labeled 53.6.7 anti-
mouse CD8a (Molecular Probes, Eugene, OR) at a 1:100 dilution for
30 min on ice. Samples were washed and fixed immediately with 2% para-
formaldehyde. Images were acquired on an LSM 510 META laser scanning
confocal microscope (Zeiss, Oberkochen, Germany) at 100magnification
at the Johns Hopkins School of Medicine Microscopy Facility.kICS
The k-space image correlation spectroscopy (kICS) imaging and analysis
were performed as described previously in Kolin et al. (26). T cells were
labeled using biotinylated Ld-QL9 monomer (NIH Tetramer Facility) at
a concentration of 2 mg/2–5  106 T cells in 100-mL PBS for 30 min on
ice and then washed once with 2-mL PBS, followed by 10-nM streptavi-
din-coated Quantum Dots 655 (Life Technologies, Carlsbad, CA) in
100-mL PBS incubated for 30 min at 4C. Labeled cells were then washed2 with 2-mL PBS before imaging. Cells were imaged using a Marianas
Live Cell Imaging Workstation (3I, Denver, CO) equipped with dual
Cascade II 512 electron-multiplying cameras (Photometrics, Tucson, AZ)
at the Johns Hopkins University Integrated Imaging Center. A quantity of
150–300 images was obtained at 300-ms intervals.
Each image series was corrected for background intensity values using
a top-hat transformation, segmented using the watershed transform, and
filtered for immobile components. Degree of aggregation was calculated by
dividing mean image intensity by clusters of differentiation, a function of
the autocorrelation of fast-Fourier-transformed image series in k-space with
a custom program written in MATLAB (The MathWorks, Natick, MA) (26).FRET
TCR-CD8 Fo¨rster resonance energy transfer (FRET) was assessed by flow
cytometry (17). Approximately 106 T cells were incubated with a 1:100
dilution of unlabeled or PE-labeled 53.6.7 anti-mouse CD8a as donor
and 500-nM uncoupled or Alexa Fluor 647-coupled Ld-QL9 (Molecular
Probes) in FACS buffer at 4C for 30min. Samples were stainedwith labeled
Ld-QL9 and anti-CD8 antibody (Eboth), labeled L
d-QL9 but unlabeled
CD8 (EA647), unlabeledL
d-QL9 but labeled anti-CD8 (EPE), or both reagents
unlabeled (Enone). FRET emission was assessed by flow cytometry on
a FACSCalibur (BD Biosciences) without compensation, with FL-3
channel for Alexa Fluor (Molecular Probes) emission without direct laser
excitation. FRET efficiency was calculated in FRET units (17,27) as
















where E1 is the fluorescence detected at 580 nm upon excitation at 488 nm,
E2 is the fluorescence detected at 670 nm upon excitation at 630 nm, and
E3 is the fluorescence detected at 670 nm upon excitation at 488 nm.Intracellular cytokine staining
Four or seven days after primary stimulation, T cell functional activity was
assessed by rechallenge with artificial antigen-presenting cells (aAPCs),
which were fabricated as described previously in Oelke and Schneck (28)
by chemical coupling of MHC dimer and anti-CD28 antibody to Dynal
Magnetic Microbeads (Life Technologies).
A quantity of 200,000 T cells was incubated in complete RPMI with the
indicated concentration of activator bead for 5 h in a round-bottom 96-well
plate in the presence of 0.2 mL GolgiPlug (BD Biosciences). Cells were
washed and fixed using a Cytofix/Cytoperm kit (BD Biosciences) according
to the manufacturer’s instructions, then stained with anti-IL-2 Alexa Fluor
647 (Molecular Probes) and anti-IFNg PE (BioLegend). Cytokine staining
was assessed by flow cytometry and frequency of cytokine functional
cells was assessed by comparison with an unstimulated control in FlowJo
(TreeStar).RESULTS
T cells stimulated with a high dose of peptide
transiently lose MHC binding
To evaluate the effects of peptide dose during stimulation
on subsequent MHC-Ig binding, splenocytes from a 2C
T cell receptor transgenic mouse (specific for peptide SIYBiophysical Journal 103(9) 1890–1898
1892 Perica et al.presented in the context of MHC allele Kb) were activated
with increasing amounts of the cognate peptide. Overall
T cell expansion was equivalent and robust (~10–15-fold)
at all antigen doses used. Specific binding was characterized
four days after activation as the difference between binding
of cognate (SIY) and noncognate (SIIN) peptide-loaded
Kb-Ig. Samples were not washed after binding which
allowed for quantitative assessment of specific binding, as
described in Materials and Methods. As shown in Fig. 1 a,
T cells stimulated with a high dose (100 mM) of peptide
showed no measurable specific binding four days after acti-
vation, whereas cells stimulated with a six-log-fold lower
dose of peptide (100 fM) did. By Day 7, both high-dose
(HD) and low-dose (LD) -activated cells specifically bound
Kb-SIY. Loss of binding is not unique to the 2C system, as
PMEL TCR transgenic T cells, which are specific for the
melanoma antigen GP100 presented in Db-Ig, show a similar
loss and recovery when stimulated with a high dose of
antigen (Fig. 1 b).
Loss of binding is not explained by changes in surface
expression of TCR and CD8 coreceptor (see Fig. S1 in the
Supporting Material). Four days after activation, surface
expression as measured by fluorescent antibody staining
was similar for TCR (Mean Fluorescence Intensity (MFI)
of 539 fluorescent units (FU) compared to 522 FU for HD
and LD cells, respectively), CD8a (455 FU and 600 FU),
and CD8b (1071 FU and 1072 FU). Differences in theFIGURE 1 Transient loss of binding induced by stimulation with high-dose an
the 2C receptor were activated with high (100 mg/mL) or low (100 fg/mL) dose
low-dose-stimulated cells, both of which had shown robust proliferation by
timepoints by comparing cognate (SIY loaded Kb, no fill) and noncognate (SIIN
While low-dose-stimulated T cells show a classic difference between cognate
difference on Day 4. Both high- and low-dose-activated cells show specific b
high- but not low-dose-activated PMEL TCR transgenic splenocytes (top righ
high and low doses, respectively, and stained with 500 nM of Db-gp100 (cogna
Biophysical Journal 103(9) 1890–1898expression level of CD8a and CD8b, as described previ-
ously in Kroger and Alexander-Miller (29,30) are prominent
seven days after activation when binding has recovered and
thus cannot account for loss of binding.Equilibrium binding assays suggest a defect
in CD8 coreceptor colocalization with TCR
To understand the role of TCR and CD8 in high-antigen-
dose-induced loss of binding, we performed equilibrium
binding experiments on HD, LD, and mixed lymphocyte
reaction (MLR, stimulated by allogeneic splenocytes) acti-
vated cells. On Day 4, HD cells bound lower amounts of
Kb-SIY at all concentrations examined (Fig. 2 a). At high
concentrations of Kb-SIY (250 nM), high-peptide-dose-
activated cells displayed sixfold lower binding than low-
dose-activated cells.
Some TCRs require CD8 engagement to specifically
bind cognate MHC-peptide, whereas others are CD8-
independent, and bind to MHC even in absence of CD8
or after CD8 blockade (31–33). The 2C TCR transgenic
system has several cognate ligands, and the alloantigen
Ld-QL9 peptide/MHC has been characterized as a CD8-
independent binding partner (31,32). HD cells, which
could not specifically bind Kb-SIY at any concentration,
bound 1 mM Ld-QL9 as well as LD- or MLR-stimulated
cells (Fig. 2 b). However, Kd for binding L
d-QL9 to HD cellstigen. (A) Specific binding. Splenocytes from TCR transgenic mice bearing
s of cognate peptide. At Day 4, viability was >70% for high and 90% for
Day 7 (10–15-fold). Specific binding was characterized at the indicated
loaded Kb, shaded fill) fluorescence intensity of 500-nM labeled MHC-Ig.
and noncognate binding, high-dose-activated cells (top left) show no such
inding on Day 7 (bottom row). (B) Loss of binding is also observed for
t). PMEL splenocytes were activated with 10 mg/mL and 10 pg/mL for
te) and Db-ASN (noncognate) MHC-Ig dimer.
FIGURE 2 Loss of binding is ligand-sensitive. (A) Kb equilibrium binding is decreased on high-dose-activated cells. Mixed-lymphocyte-reaction- (MLR,
solid square), high-dose- (HD, solid circle), and low-dose- (LD, open circle) activated splenocytes were bound to increasing doses of cognate Kb-SIY and
noncognate Kb-SIIN. Mean MFI was measured without washing and specific binding characterized as the difference between cognate and noncognate
binding. (B) Ld equilibrium binding is equivalent for HD-, LD-, and MLR-activated cells at a high concentration of Ld (500 nM), but HD cells had fourfold
higher Kd. Binding was calculated as difference between cognate (L
dQL9) and noncognate (LdmCMV) fluorescence. (C) Relative CD8 dependence of Kb
and (D) independence of Ld binding to 2C T cells. Specific binding of 500 nMMHC-Ig was calculated as above with (solid) and without (open) simultaneous
addition of CD8-blocking antibody CT-CD8a.
Lateral Association of TCR/Coreceptor 1893was 423 mM compared to 117 mM for LD cells. Day 7
recovery from loss of binding was seen with both Kb-SIY
and Ld-QL9 ligands with complete recovery of Kd and
a decreased off-rate for Ld-QL9 (see Fig. S2).
To confirm differential CD8 sensitivity, we incubated
500 nM of MHC-Ig either alone or with 20-fold molar
excess of the CD8-blocking antibody CT-CD8a. As
described previously (31,32), CD8 blocking antibody
CT-CD8a was able to completely inhibit all specific binding
of Kb-SIY MHC-Ig for all three cell samples (Fig. 2 c). The
relative CD8-independence of 2C for Ld-QL9 was
confirmed by the insensitivity of Ld-QL9 binding to Day-4
stimulated cells in the presence of CD8 blocking antibody
(Fig. 2 d).Spatial segregation of CD8 and TCR
The ability of high-dose-activated cells to bind the CD8-
independent Ld-QL9 but not CD8-dependent Kb-SIY
implicates the CD8 coreceptor in loss of binding. Because
CD8-dependent binding was impaired but CD8 expression
was unchanged, we examined the relative spatial organi-
zation of TCR and CD8. We hypothesized that four days
after high-dose peptide activation, TCR and CD8 may notbe colocalized on the T cell membrane, and so CD8 could
not assist in MHC binding.
The clustering of TCR and CD8 was examined with
k-space image correlation spectroscopy (kICS), an image
analysis technique that extends the intracellular-cytokine-
staining approach to quantum-dot labels (26). The kICS
technique allows the measurement of degree of aggregation
(DA), with large DAs indicating that the labeled receptor
is highly clustered at scales of hundreds of nanometers
(Fig. 3 a). DA were normalized to naive cells and reported
as fold-change from naive. HD cells had less clustered
TCRs than naive (0.57-fold naive). In contrast, LD (1.67)
and MLR cells (2.20) had more clustered TCRs (Fig. 3 b).
For CD8, HD (2.19), LD (3.24), and MLR (2.90) cells
were all more clustered than naive cells. This finding
suggests that TCR and CD8 may be organized in different
membrane subdomains on the surface of high-dose-
activated T cells. By Day 7, both CD8 and TCR were
more clustered on all activated samples compared to naive,
such that the degree of TCR clustering correlated with Kb
binding (see Fig. S3).
Confocal microscopy was used to measure differences
in CD8 and TCR colocalization. HD cells showed a signif-
icantly lower degree of colocalization (Pearson’sBiophysical Journal 103(9) 1890–1898
FIGURE 3 TCR and CD8 colocalization and clustering characteristics at optical scales. (A) The k-space image correlation spectroscopy (kICS). (Left)
Schematic of receptor clusters illustrates degree of aggregation (DA) is calculated as mean image intensity divided by discrete receptor clusters measured
on the cell. For a given cell, a high DA indicates that the fluorescently labeled receptors are aggregated into a small number of discrete clusters, and a low
DA indicates that receptors are diffusely distributed across the cell. (Top right) Representative epifluorescent images used for kICS analysis show an
HD-stimulated cell with 0.98 DA, compared to 2.60 DA for the LD-stimulated cell (bottom right). (B) TCRs but not CD8 are comparatively unclustered
on HD cells. Four days after activation, HD-, LD-, and MLR-activated splenocytes were assessed by kICS. DA for individual cells is represented in the
dot plot, with median DA for the sample shown (black bar). DAwas normalized to the median DA for a sample of naive T cells, as shown (light-gray dashed
line). DA for TCR on HD cells was lower than naive and significantly different (p < 0.05, black bars) from LD and MLR cells. (C) Representative confocal
images of HD- (top) and LD- (bottom) activated cell for TCR (green), CD8 (red), and colocalized TCR/CD8 (white). (D) TCR/CD8 colocalization correlates
with loss and recovery of binding. Degree of colocalization was calculated by Pearson’s correlation coefficient on at least 15 cells four and seven days
after activation. HD cells had significantly less colocalization (p < 0.05, star) on Day 4 compared to LD cells. In contrast, both samples have relatively
high colocalization on Day 7 when both can bind.
1894 Perica et al.correlation coefficient 0.45 5 0.02) between TCR
and CD8 than LD cells (0.61 5 0.03) on Day 4 (Fig. 4
a). On Day 7, when the binding defect had recovered,
both HD and LD cells exhibit large Pearson’s correla-
tion coefficients of 0.70 5 0.02 and 0.74 5 0.02,
respectively.CD8 and TCR are not colocalized at the nanoscale
on high-dose-activated cells
Because CD8 must be located within tens of nanometers to
TCR to assist in MHC binding, we assessed the colocaliza-
tion of TCR and CD8 at the nanoscale by Fo¨rster resonance
energy transfer (FRET). FRET is the nonradiative transfer of
energy from a directly excited donor fluorophore to an
acceptor fluorophore; this only occurs when they are within
10 nm of each other, hence FRET is a measure of nanoscale
colocalization (34). HD and LD cells were labeled with
fluorescently tagged Ld-QL9 and anti-CD8 antibody.
FRETwas observed as a relative increase in the fluorescenceBiophysical Journal 103(9) 1890–1898intensity of the acceptor fluorophore when MHC-Ig and
CD8 were fluorescently labeled with the appropriate
FRET pair.
Approximately 97% of naive CD8 T cells showed nano-
scale colocalization of CD8 and TCR by FRET (Fig. 4 a).
Similarly, a majority of LD- and MLR-activated cells
displayed a FRET shift. However, only ~30% of HD cells
displayed a FRET shift (Fig. 4 a), consistent with reduced
CD8-TCR colocalization. The amount of nanoscale colocal-
ization can be quantified in FRET units as a normalized
shift in acceptor intensity (27). As shown in Fig. 4 b, HD
cells have a decreased FRET intensity of 16 FRET units
compared to LD (62 units) or naive (43 units) cells. Reduced
FRETwas not due to a decrease in CD8 or MHC-Ig binding
in HD cells (see Fig. S3), because coreceptor expression is
unchanged and CD8-indpendent Ld-QL9 does not display
loss of binding.
FRET intensity recovered for HD cells from Day 4 to
Day 7 (Fig. 4 c), while FRET was consistently high when
observed on LD and MLR cells throughout. FRET thus
FIGURE 4 Reduced nanoscale colocalization of TCR and CD8 on high-dose-activated cells revealed by FRET. (A) Four days after activation, naive, HD-,
LD-, and MLR-activated T cells were bound to 500 nM Ld-QL9 dimer and anti-CD8 antibody at 4C. Background fluorescence was assessed with unlabeled
acceptor (MHC-Ig) and PE-labeled donor (CD8) (left column). FRET manifests as a shift in fluorescence intensity in the FRET channel (acceptor emission
with no acceptor laser excitation) when bothMHC-Ig and CD8 are labeled with fluorophore (right column). HD cells show the smallest shift as represented by
the percentage of cells found in FRET gate. FRET units are a normalized measure of FRET shift (as described in Materials and Methods) for all samples. (B)
FRET shift four days after activation. High-dose-activated cells show the lowest degree of FRET shift compared to naive, LD, or MLR. (C) Day 7 FRETunits
show recovery in high-dose nanoscale colocalization which correlates with recovery in Kb binding.
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TCR and CD8 on high-dose-activated cells.Production of cytokine IFNg correlates with CD8-
dependent binding
The functional consequences of changes in binding of
cognate ligand were assayed by intracellular cytokine stain-
ing assay, which measures T cell production of cytokine in
response to antigen. Four or seven days after activation,
T cells were rechallenged with an aAPC (28), a bead-based
T cell activation platform presentingMHC-Ig and a costimu-
latory signal (Fig. 5).As seen in Fig. 5 a, T cells were capable of producing the
cytokine IFNg when stimulated with phorbol 12-myristate
13-acetate and ionomycin, stimuli that bypass the TCR.
Thus, any functional defects observed when T cells are
stimulated via their TCR are not due to downstream
defects in T cell signaling, but to signals received by the
TCR itself.
When T cells were restimulated with Kb-SIY aAPC four
days after stimulation, <20% of HD cells produced IFNg
at all aAPC-cell ratios examined. In comparison, up to
55% of LD cells were responsive (Fig. 5 b). However,
both cell populations were able to produce high levels
of IFNg in response to an Ld-QL9 presenting aAPC
(Fig. 5 c). Functional response of HD cells to Ld-QL9 butBiophysical Journal 103(9) 1890–1898
FIGURE 5 Functional responses correlate with
binding defects. (A) HD or LD cells are capable
of producing the cytokine IFNg when restimulated
on Day 4 (open) or Day 7 (shaded) after activation
with phorbol 12-myristate 13-acetate and ionomy-
cin, which activate T cells downstream of the TCR.
IFNg production was measured by intracellular-
cytokine staining and quantified as the percentage
of cells producing cytokine. (B–D) T cells were
restimulated with beads bearing Ld-QL9 or Kb-
SIY dimer and CD28 costimulatory antibody on
Days 4 or 7 at the indicated T cell/bead ratios (x
axis). No stimulation and noncognate beads (at a
bead/cell 10:1 ratio) were used as negative control.
With Day 4 Kb stimulation, LD cells showed dose-
dependent IFNg production that was significantly
lower in high-dose cells (top left). However, both
HD and LD cells stimulated with Ld-containing
beads on Day 4 (bottom left) were able to produce
cytokine. The difference between HD and LD cells
had partially recovered on Day 7 (top right).
1896 Perica et al.not Kb-SIY correlates with observed binding on Day 4.
Again, similarly to binding, HD cells recovered functionally
by Day 7, when up to 42% of cells produced the cytokine in
response to a Kb-SIY-based aAPC (Fig. 5 d).DISCUSSION
In this study, we show that T cells dynamically regulate the
organization of their receptor for antigen in response to acti-
vation signals, with consequences for MHC binding and
thus functional response. T cells were activated by a high
dose of antigen-bound CD8-independent but not CD8-
dependent MHC-Ig. This difference was associated with
a loss of colocalization at the nanoscale as measured by
FRET between TCR and CD8. Decreased FRET in HD cellsBiophysical Journal 103(9) 1890–1898may be due to either a true loss of colocalization indepen-
dent of MHC-Ig binding, or to a loss in the ability of
MHC-Ig to induce TCR/CD8 clustering (35,36). We
observe no differences in the ability of MHC to indepen-
dently bind TCR or CD8. Therefore, decreased FRET
represents either a loss of colocalization in the resting state
or an inability for CD8 and TCR to colocalize once they
bind MHC. As a result, T cells are unable to produce cyto-
kines in response to antigen challenge by CD8-sensitive
antigen. The effect is transient, with colocalization, binding,
and function recovering over time.
Thus, despite the presence of identical receptors,
activated T cells derived from the same precursor may
have different surface receptor organization and different
antigen-binding properties based on their history of antigen
Lateral Association of TCR/Coreceptor 1897exposure. FRET and coimmunoprecipitation studies have
shown TCR and CD8 both are (37–39) and are not
(27,36,40) colocalized at the nanoscale on resting T cells.
We suggest that differences in antigen exposure and timing
may be the source of conflicting results. Similarly, antigen
exposure is likely responsible for conflicting reports of
enhanced binding (15) or loss of binding (16–20) after
activation.
The mechanism underlying dynamic T cell membrane
organization remains unclear. TCR and CD8 (41,42) are
known to preferentially segregate in lipid rafts during stim-
ulation and interact with the galectin-glycan lattice (43).
Recently, Demotte et al. (16) demonstrated that exogenous
galectin treatment could reverse a tumor-induced defect in
TCR-CD8 colocalization and binding, adding to evidence
that interaction of galectins with N-linked glycosylation
sites on TCR controls sensitivity of T cell responses (44).
Long-term control of membrane organization could thus
involve changes in lipid rafts, surface receptor glycosyla-
tion, and both endogenous and exogenous secretion of
receptor-binding galectins. However, great care needs to
be taken to identify mechanisms that operate seconds and
minutes after T cell activation, as well as those mechanisms
that control more-persistent membrane changes.
Persistent TCR clustering and TCR-CD8 colocalization
coexist with and may be mechanistically related to more
transient changes that occur upon exposure to antigen.
TCR on a resting naive T cell are organized in small nano-
clusters (14,45) which concatenate (10) when the T cell
encounters antigen. These signaling microclusters are
thought to represent early signaling platforms upon which
downstream kinases and scaffolding proteins assemble and
activate (46). With sustained, robust stimulation, signaling
microclusters migrate to the center of the microscale
immune synapse, where they are degraded (11,12). Many
days after stimulation, T cells’ membranes retain memory
of the previous activation event, with more highly clustered
TCR than naive cells (13,15,25) and different levels of CD8
colocalization depending on the strength of initial stimu-
lation. These membrane structures can potentially affect
both binding of antigen and the activation of downstream
signaling proteins.
It is well established that in chronic viral infections and
cancer, sustained exposure to low-dose antigen induces
dysfunctional T cell responses (47,48). We demonstrate
that an acute exposure to high-dose antigen in vitro can
induce transient functional and binding defects, although
this finding must be confirmed at physiological antigen
doses in vivo. Long-term antigen-dose-driven responses
also include binding-independent functional defects
(29,30) and a tendency toward effector compared to
memory phenotypes as a result of acute high-dose stimula-
tion (49). We thus suggest that antigen-induced loss of
binding is an intrinsic T cell response to high-dose antigen
stimulation, and need not be associated with the tumormicroenvironment (17). Membrane-organization-induced
loss of binding may serve as a regulatory mechanism to
avoid excessive inflammation and immunopathology in
response to aggressive infection.SUPPORTING MATERIAL
Four figures are available at http://www.biophysj.org/biophysj/supplemental/
S0006-3495(12)01024-7.
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